Zhaoke Ophthalmology (FRA:9FX) Loans Receivable: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9FX Zhaoke Ophthalmology Ltd FRA:9FX
47 GF Score
Price €0.26
GF Value €0.27
! 5 Warning Signs
View Full Analysis

What is Zhaoke Ophthalmology Loans Receivable?

Zhaoke Ophthalmology FRA:9FX +0.78% 47 Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:9FX with a GF Score™ of 47/100 and a GF Value™ of €0.27. The stock has 5 warning signs investors should review.

Zhaoke Ophthalmology's Loans Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Zhaoke Ophthalmology Loans Receivable Related Terms

Zhaoke Ophthalmology Loans Receivable Historical Data

* Premium members only.

The historical data trend for Zhaoke Ophthalmology's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhaoke Ophthalmology Loans Receivable Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:9FX
47GF Score
Zhaoke Ophthalmology Ltd FRA:9FX
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhaoke Ophthalmology Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
Zhaoke Ophthalmology (FRA:9FX) has a Loans Receivable of €0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Zhaoke Ophthalmology and its competitors.
Is Zhaoke Ophthalmology's Loans Receivable too high?
Zhaoke Ophthalmology's current Loans Receivable is €0.00 Mil. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Loans Receivable compare to VRTX and REGN?
Zhaoke Ophthalmology's Loans Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Zhaoke Ophthalmology and its competitors. Zhaoke Ophthalmology's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Zhaoke Ophthalmology (FRA:9FX) has a current Loans Receivable of €0.00 Mil. The stock's GF Value™ is €0.27, compared to a current price of €0.26 — trading 4.4% below its estimated fair value. The current Loans Receivable is €0.00 Mil. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Zhaoke Ophthalmology (FRA:9FX), the current Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhaoke Ophthalmology (FRA:9FX) Overvalued in 2026?

Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued. The current stock price of €0.26 is trading 4.4% below its estimated GF Value™ of €0.27.

Key valuation signals for FRA:9FX:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €0.27 vs. price of €0.26 (4.4% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:9FX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhaoke Ophthalmology Business Description

Other Exchanges 06622:Hong Kong
Address No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score

Get the complete analysis for FRA:9FX

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price
€0.27
GF Value